Table 2.
Comparison of characteristics of responders and nonresponders to CD34+ cell therapy. Values are presented as mean ± SD, number of patients (percent), or median (IQR) for NT-proBNP.
| Nonresponders (N = 18) | Responders (N = 43) | p | |
|---|---|---|---|
| Age (y) | 55 ± 10 | 51 ± 13 | 0.32 |
| Male gender (%) | 15 (85) | 36 (84) | 0.96 |
| Nonischemic CMP (%) | 13 (72) | 29 (67) | 0.67 |
| LVEF (%) | |||
| Baseline | 27 ± 6 | 31 ± 5 | <0.05 |
| 3 months | 28 ± 6 | 39 ± 7 | <0.05 |
| 6MWT (m) | 464 ± 101 | 490 ± 73 | 0.28 |
| NT-proBNP (pg/mL (IQR)) | 3245 (1584-4336) | 609 (240-1323) | <0.05 |
| Creatinine (mmol/L) | 101 ± 30 | 79 ± 16 | <0.05 |
| Bilirubin (μmol/L) | 17 ± 9 | 16 ± 8 | 0.48 |
| Sodium (mmol/L) | 140 ± 2 | 141 ± 2 | 0.84 |
| AST (μmol/L) | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.10 |
| AF (μmol/L) | 1.2 ± 0.4 | 1.1 ± 0.4 | 0.60 |
| gGT (μmol/L) | 1.2 ± 1.3 | 1.1 ± 1.4 | 0.68 |
| RDW (%) | 14.3 ± 1.4 | 13.4 ± 0.9 | 0.01 |
| Leukocytes (×109) | 7.1 ± 1.9 | 7.1 ± 1.4 | 0.85 |
| Hemoglobin (g/L) | 142 ± 14 | 144 ± 10 | 0.44 |
| Platelet count (×109) | 207 ± 69 | 209 ± 37 | 0.89 |
| Medical management | |||
| ACEI/ARB | 18 (100) | 42 (100) | / |
| Beta blockers | 18 (100) | 42 (100) | / |
| MRA | 18 (100) | 42 (100) | / |
| Diuretic | 12 (67) | 21 (48) | 0.24 |
| Aspirin | 7 (39) | 26 (60) | 0.13 |
| Galectin-3 levels (ng/mL) | |||
| Baseline | 13.2 ± 4.9 | 13.6 ± 5.7 | 0.80 |
| 3 months | 15.7 ± 8.4 | 12.1 ± 4.0 | <0.05 |
ICMP: ischemic cardiomyopathy; DCMP: nonischemic cardiomyopathy; LVEF: left ventricular ejection fraction; 6MWT: 6-minute walk test; AST: aspartate transaminase; AF: alkaline phosphatase; gGT: γ-glutamyltranspeptidase; RDW: red cell distribution width; ACEI: angiotensin convertase inhibitor; ARB: angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonist.